U.S. Markets open in 7 hrs 33 mins
  • S&P Futures

    4,128.00
    +4.50 (+0.11%)
     
  • Dow Futures

    33,942.00
    +8.00 (+0.02%)
     
  • Nasdaq Futures

    12,534.00
    +18.50 (+0.15%)
     
  • Russell 2000 Futures

    1,967.50
    +2.40 (+0.12%)
     
  • Crude Oil

    75.27
    +1.16 (+1.57%)
     
  • Gold

    1,888.20
    +8.70 (+0.46%)
     
  • Silver

    22.44
    +0.20 (+0.91%)
     
  • EUR/USD

    1.0743
    +0.0013 (+0.1182%)
     
  • 10-Yr Bond

    3.6340
    0.0000 (0.00%)
     
  • Vix

    19.43
    +1.10 (+6.00%)
     
  • GBP/USD

    1.2049
    +0.0025 (+0.2084%)
     
  • USD/JPY

    132.0980
    -0.5090 (-0.3838%)
     
  • BTC-USD

    22,948.62
    +142.42 (+0.62%)
     
  • CMC Crypto 200

    526.84
    +1.70 (+0.32%)
     
  • FTSE 100

    7,836.71
    -65.09 (-0.82%)
     
  • Nikkei 225

    27,685.47
    -8.18 (-0.03%)
     

Aurinia Pharmaceuticals Third Quarter 2022 Earnings: Beats Expectations

Aurinia Pharmaceuticals (NASDAQ:AUPH) Third Quarter 2022 Results

Key Financial Results

  • Revenue: US$55.8m (up 280% from 3Q 2021).

  • Net loss: US$8.99m (loss narrowed by 82% from 3Q 2021).

  • US$0.063 loss per share (improved from US$0.39 loss in 3Q 2021).

earnings-and-revenue-growth
earnings-and-revenue-growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Aurinia Pharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 53%. Earnings per share (EPS) also surpassed analyst estimates by 69%.

Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 38% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 2 warning signs for Aurinia Pharmaceuticals you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here